(ATNM) - Earnings & Price History

ATNM: - 0.6472, $53.28M, 0.02 (3.57%)

Sector: Healthcare - Industry: Biotechnology

Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted payload immunotherapeutics for the treatment of advanced cancers. The companys targeted radio immunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213, and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. Its lead radiopharmaceutical product candidate is Iomab-B that is in Phase 3 clinical studies in refractory or relapsed acute myeloid leukemia (AML) patients over the age of 55 for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The company is also developing Actimab-A, which is in Phase 1/2 clinical trials for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial. Actinium Pharmaceutical, Inc. was founded in 2000

Past ATNM reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume

Login | Register
Saturday Sep 21, 2019   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR


index chart
index color